Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Southern African Journal of HIV Medicine|September 1, 2018
Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization's algorithm for seriously ill HIV-infected patientsGary Maartens, Annemie Stewart, Rulan Griesel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 16, 2023
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled TrialYing Zhao, Rulan Griesel, Zaayid Omar, et al.
The Lancet. HIV|May 25, 2023
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trialRulan Griesel, Ying Zhao, Bryony Simmons, et al.
The Journal of Antimicrobial Chemotherapy|August 29, 2022
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African populationRulan Griesel, Phumla Sinxadi, Aida Kawuma, et al.
British Journal of Clinical Pharmacology|December 26, 2021
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapyRulan Griesel, Aida N Kawuma, Roeland Wasmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2017
Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus-Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization AlgorithmRulan Griesel, Annemie Stewart, Helen van der Plas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2024
Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral TherapyJennifer Kate van Heerden, Graeme Meintjes, David Barr, et al.
Southern African Journal of HIV Medicine|May 13, 2025
Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ARTJennifer K van Heerden, Ying Zhao, Claire M Keene, et al.
Wellcome Open Research|August 26, 2022
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialYing Zhao, Claire Keene, Rulan Griesel, et al.
Infectious Diseases and Therapy|April 26, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIVNilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Pageof 3